Riddell, Michael C.Aleali, Nadia2025-04-102025-04-102024-08-152025-04-10https://hdl.handle.net/10315/42749This thesis examined whether a novel somatostatin receptor 2 antagonist (SSTR2a), ZT-01, could enhance endogenous glucagon secretion and protect against hypoglycemia in a rat model of type 2 diabetes (T2D). Male Sprague Dawley rats were placed on a high-fat diet and injected with streptozotocin to induce T2D. The rats were then chronically treated with varying doses of ZT-01 or vehicle using implanted mini-osmotic pumps. While ZT-01 did not significantly affect basal glucose levels or oral glucose tolerance, it tended to increase baseline glucagon levels and the glucagon response to insulin-induced hypoglycemia, though the effects were small. Overall, sustained exposure to SSTR2a modestly improved the glucose and glucagon response to insulin-induced hypoglycemia in this T2D model, suggesting the potential for this approach to prevent hypoglycemia in insulin-requiring T2D.Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests.Electronic Thesis or Dissertation2025-04-10DiabetesType 2 DiabetesPharmacologyDrug developmentSomatostatinGlucagonInsulinInsulin-requiringOsmotic pumpsSustained-releaseSomatostatin receptor 2 antagonistSSTR2a